title: Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas.
abstract: Using a dominant-negative mutant receptor (DNR) approach in transgenic mice, we have functionally inactivated transforming growth factor-beta (TGF-beta) signaling in select epithelial cells. The dominant-negative mutant type II TGF-beta receptor blocked signaling by all three TGF-beta isoforms in primary hepatocyte and pancreatic acinar cell cultures generated from transgenic mice, as demonstrated by the loss of growth inhibitory and gene induction responses. However, it had no effect on signaling by activin, the closest TGF-beta family member. DNR transgenic mice showed increased proliferation of pancreatic acinar cells and severely perturbed acinar differentiation. These results indicate that TGF-beta negatively controls growth of acinar cells and is essential for the maintenance of a differentiated acinar phenotype in the exocrine pancreas in vivo. In contrast, such abnormalities were not observed in the liver. Additional abnormalities in the pancreas included fibrosis, neoangiogenesis and mild macrophage infiltration, and these were associated with a marked up-regulation of TGF-beta expression in transgenic acinar cells. This transgenic model of targeted functional inactivation of TGF-beta signaling provides insights into mechanisms whereby loss of TGF-beta responsiveness might promote the carcinogenic process, both through direct effects on cell proliferation, and indirectly through up-regulation of TGF-betas with associated paracrine effects on stromal compartments.
authors.affiliation: Laboratory of Chemoprevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: E P
authors.initials: EP
authors.lastname: Böttinger
authors.forename: J L
authors.initials: JL
authors.lastname: Jakubczak
authors.forename: I S
authors.initials: IS
authors.lastname: Roberts
authors.forename: M
authors.initials: M
authors.lastname: Mumy
authors.forename: P
authors.initials: P
authors.lastname: Hemmati
authors.forename: K
authors.initials: K
authors.lastname: Bagnall
authors.forename: G
authors.initials: G
authors.lastname: Merlino
authors.forename: L M
authors.initials: LM
authors.lastname: Wakefield
mesh_terms: D000818:Animals; D017209:Apoptosis; D002454:Cell Differentiation; D002455:Cell Division; D005353:Fibronectins / Q000378:metabolism; D015870:Gene Expression; D006706:Homeostasis; D007150:Immunohistochemistry; D008099:Liver / Q000378:metabolism; D008668:Metallothionein / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation; D010179:Pancreas / Q000002:abnormalities / Q000254:growth & development*; D010190:Pancreatic Neoplasms / Q000209:etiology; D010641:Phenotype; D018809:Proliferating Cell Nuclear Antigen / Q000302:isolation & purification; D011401:Promoter Regions, Genetic; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000172:deficiency / Q000235:genetics*; D015398:Signal Transduction; D016212:Transforming Growth Factor beta / Q000378:metabolism*
chemical_list: D005353:Fibronectins; D018809:Proliferating Cell Nuclear Antigen; D018125:Receptors, Transforming Growth Factor beta; D016212:Transforming Growth Factor beta; D008668:Metallothionein; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II